UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 35

Sortiert nach

Bisphosphonate Use in Patients with Lung Cancer and Bone Metastases: Recommendations of a European Expert Panel

Journal of thoracic oncology, 2009-10, Vol.4 (10), p.1280-1288

2009

Volltextzugriff (PDF)

Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study

Clinical cancer research, 2015-04, Vol.21 (8), p.1896-1903

2015

Volltextzugriff (PDF)

BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers

The European respiratory journal, 2015-05, Vol.45 (5), p.1403-1414

2015

Volltextzugriff (PDF)

Thymic metastasis from lung carcinoma

Interactive cardiovascular and thoracic surgery, 2011-05, Vol.12 (5), p.848-849

2011

Volltextzugriff (PDF)

Histomolecular Resistance Mechanisms to First-Line Osimertinib in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multicentric Retrospective French Study

Targeted oncology, 2022-11, Vol.17 (6), p.675-682

2022

Volltextzugriff (PDF)

Neurotensin (NTS) and its receptor (NTSR1) causes EGFR, HER2 and HER3 over-expression and their autocrine/paracrine activation in lung tumors, confirming responsiveness to erlotinib

Oncotarget, 2014-09, Vol.5 (18), p.8252-8269

2014

Volltextzugriff (PDF)

Efficacy of extracranial stereotactic body radiation therapy

BMC cancer, 2021-02, Vol.21 (1)

2021

Volltextzugriff (PDF)

Abstract 4304: Radio-chemotherapy efficacy is predicted by intra-tumor CD8+FoxP3+ double positive T cell density in locally advanced non-small cell lung carcinoma

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.4304-4304

2020

Volltextzugriff (PDF)

Impact of country of birth on genetic testing of metastatic lung adenocarcinomas in France: African women exhibit a mutational spectrum more similar to Asians than to Caucasians

Oncotarget, 2017-08, Vol.8 (31), p.50792-50803

2017

Volltextzugriff (PDF)

Real-life efficacy and safety of nivolumab for non-small cell lung cancer: A 10-months French cohort

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e20633-e20633

2016

Volltextzugriff (PDF)

Challenges in Diagnosis and Treatment of Lung Cancer in People with Intellectual Disabilities: Current State of Knowledge

Biotechnology research international, 2016, Vol.2016, p.1-7

2016

Volltextzugriff (PDF)

2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: report from the working group

Annals of oncology, 2009-09, Vol.20 (9), p.1459-1471

2009

Volltextzugriff (PDF)

Pharmacotherapy Update: Vinorelbine in the Treatment of Non-small-cell Lung Cancer

Clinical medicine insights. Therapeutics, 2010-01, Vol.2, p.179

2010

Volltextzugriff (PDF)

Association between lung cancer somatic mutations and occupational exposure in never-smokers

The European respiratory journal, 2017-10, Vol.50 (4), p.1700716-1700716

2017

Volltextzugriff (PDF)

Real-life use of nivolumab in non-small cell lung cancer: A multicentric cohort to determine its clinical efficacy and predictive factors of early progression

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e20543-e20543

2017

Volltextzugriff (PDF)

Lung cancers in the elderly

Bulletin du cancer, 2008-05, Vol.95 FMC Onco, p.F57

2008

Volltextzugriff (PDF)

No impact of passive smoke on the somatic profile of lung cancers in never-smokers

The European respiratory journal, 2015-05, Vol.45 (5), p.1415-1425

2015

Volltextzugriff (PDF)

Use of Adjuvant Chemotherapy in Non-small Cell Lung Cancer in Routine Practice

Journal of thoracic oncology, 2009-12, Vol.4 (12), p.1504-1510

2009

Volltextzugriff (PDF)

Abstract 2231: The prevalence of EGFR and KRAS mutations in a population of African immigrants in France is closer to that of Asian populations than to white Europeans

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.2231-2231

2014

Volltextzugriff (PDF)

Risk factors for early mortality from lung cancer: evolution over the last 20 years in the French nationwide KBP cohorts

ESMO open, 2024-06, Vol.9 (6), p.103594, Article 103594

2024

Volltextzugriff (PDF)

P3.02a-034 Vemurafenib in Patients with Non-Small Cell Lung Cancer (NSCLC) Harboring BRAF Mutation. Preliminary Results of the AcSé Trial

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S1182-S1183

2017

Volltextzugriff (PDF)

P3.02a-034 Vemurafenib in Patients with Non-Small Cell Lung Cancer (NSCLC) Harboring BRAF Mutation. Preliminary Results of the AcSé Trial: Topic: Miscellaneous

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S1182-S1183

2017

Volltextzugriff (PDF)

Phase II study of cetuximab, pemetrexed, cisplatin and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non-squamous, non-small cell lung cancer (NSCLC): Results of the IFCT-0803 trial

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.7511-7511

2014

Volltextzugriff (PDF)

Adenocarcinoma of the Lung in down Syndrome: First Clinical Report

Tumori, 2013-07, Vol.99 (4), p.169-171

2013

Volltextzugriff (PDF)

1 – 25 von 35

Suche als RSS-Feed

Aktive Filter

KollektionElsevier ScienceDirect Journals Complete

KollektionIngentaConnect Journals

ThemaBiological And Medical Sciences

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(31)
Mit Volltextzugriff
(32)

Publikationsform

Artikel
(35)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Bisphosphonate Use in Patients with Lung Cancer and Bone Metastases: Recommendations of a European Expert Panel

Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study

BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers

Thymic metastasis from lung carcinoma

Histomolecular Resistance Mechanisms to First-Line Osimertinib in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multicentric Retrospective French Study

Neurotensin (NTS) and its receptor (NTSR1) causes EGFR, HER2 and HER3 over-expression and their autocrine/paracrine activation in lung tumors, confirming responsiveness to erlotinib

Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial

Efficacy of extracranial stereotactic body radiation therapy

Abstract 4304: Radio-chemotherapy efficacy is predicted by intra-tumor CD8+FoxP3+ double positive T cell density in locally advanced non-small cell lung carcinoma

Impact of country of birth on genetic testing of metastatic lung adenocarcinomas in France: African women exhibit a mutational spectrum more similar to Asians than to Caucasians

Real-life efficacy and safety of nivolumab for non-small cell lung cancer: A 10-months French cohort

Challenges in Diagnosis and Treatment of Lung Cancer in People with Intellectual Disabilities: Current State of Knowledge

2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: report from the working group

Pharmacotherapy Update: Vinorelbine in the Treatment of Non-small-cell Lung Cancer

Association between lung cancer somatic mutations and occupational exposure in never-smokers

Real-life use of nivolumab in non-small cell lung cancer: A multicentric cohort to determine its clinical efficacy and predictive factors of early progression

Lung cancers in the elderly

No impact of passive smoke on the somatic profile of lung cancers in never-smokers

Use of Adjuvant Chemotherapy in Non-small Cell Lung Cancer in Routine Practice

Abstract 2231: The prevalence of EGFR and KRAS mutations in a population of African immigrants in France is closer to that of Asian populations than to white Europeans

Risk factors for early mortality from lung cancer: evolution over the last 20 years in the French nationwide KBP cohorts

P3.02a-034 Vemurafenib in Patients with Non-Small Cell Lung Cancer (NSCLC) Harboring BRAF Mutation. Preliminary Results of the AcSé Trial

P3.02a-034 Vemurafenib in Patients with Non-Small Cell Lung Cancer (NSCLC) Harboring BRAF Mutation. Preliminary Results of the AcSé Trial: Topic: Miscellaneous

Phase II study of cetuximab, pemetrexed, cisplatin and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non-squamous, non-small cell lung cancer (NSCLC): Results of the IFCT-0803 trial

Adenocarcinoma of the Lung in down Syndrome: First Clinical Report

Aktive Filter

Suchergebnisse filtern